• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.

作者信息

Thom A K, Alexander H R, Andrich M P, Barker W C, Rosenberg S A, Fraker D L

机构信息

Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

出版信息

J Clin Oncol. 1995 Jan;13(1):264-73. doi: 10.1200/JCO.1995.13.1.264.

DOI:10.1200/JCO.1995.13.1.264
PMID:7799030
Abstract

PURPOSE

Isolated limb perfusion (ILP) with tumor necrosis factor (TNF), interferon gamma, and melphalan (M) has been reported to result in high response rates for extremity melanoma and sarcoma. We have evaluated the relationship of systemic TNF exposure to induction of several secondary mediators and incidence of systemic toxicity.

PATIENTS AND METHODS

Nineteen patients with extremity melanoma (n = 16) or sarcoma (n = 3), underwent 90-minute ILP with TNF-alpha, interferon gamma (0.2 mg), and M (10 to 13 mg/L of limb volume) (TNF/IFN/M) (n = 12), or M alone (n = 7). Continuous intraoperative monitoring (CIM) for systemic leak from the perfusion circuit was performed using radioactive iodine-131 albumin. Cytokine levels in the perfusate and systemic circulation during and after ILP were measured by enzyme-linked immunosorbent assay.

RESULTS

Systemic leaks > or = 1% from the perfusion circuit occurred in six patients who received TNF/IFN/M and in four who received M alone. Hypotension that required vasopressor support occurred in six of six patients with evidence of a leak (> or = 1%) and zero of six patients without a leak (< 1%). These six patients had significantly higher peak systemic TNF levels during and after perfusion than patients without a leak (2.8 and 8.2 ng/mL v 0.7 and 2.0 ng/mL, respectively; P < .05). All patients who received TNF/IFN/M had significantly greater increases in systemic interleukin-6 (IL-6) levels than in patients with M alone (12,395 +/- 10,374 pg/mL v 79.4 +/- 7.2 pg/mL, respectively; P < .001). Intracellular adhesion molecule (ICAM), IL-8, and TNF-R levels were also increased after ILP with TNF/IFN/M.

CONCLUSION

ILP with TNF/IFN/M can be safely performed, as I131 albumin provides a sensitive measure of systemic leakage from the perfusion circuit. Patients with a measured leak of > or = 1% develop mild and transient postoperative hypotension with significantly higher systemic TNF levels and lower perfusate TNF levels than in patients without leaks.

摘要

相似文献

1
Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.
J Clin Oncol. 1995 Jan;13(1):264-73. doi: 10.1200/JCO.1995.13.1.264.
2
Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.使用美法仑、肿瘤坏死因子和干扰素γ进行热灌注隔离肢体治疗肢体黑色素瘤患者:肿瘤坏死因子剂量递增研究结果
J Clin Oncol. 1996 Feb;14(2):479-89. doi: 10.1200/JCO.1996.14.2.479.
3
Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan.在采用肿瘤坏死因子-α和美法仑进行渗漏控制的离体肢体灌注后未出现严重的全身毒性。
Ann Surg Oncol. 1999 Jun;6(4):405-12. doi: 10.1007/s10434-999-0405-9.
4
High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.高剂量重组肿瘤坏死因子α联合干扰素γ和美法仑用于肢体隔离灌注治疗黑色素瘤和肉瘤
J Clin Oncol. 1992 Jan;10(1):52-60. doi: 10.1200/JCO.1992.10.1.52.
5
Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma.单独使用肿瘤坏死因子进行黑色素瘤的热灌注隔离肢体治疗。
Cancer J Sci Am. 1995 Nov-Dec;1(4):274-80.
6
Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors.不可切除软组织肿瘤患者联合放疗与肿瘤坏死因子α±干扰素γ及美法仑进行隔离肢体灌注的并发症
J Surg Oncol. 1997 Jun;65(2):88-94. doi: 10.1002/(sici)1096-9098(199706)65:2<88::aid-jso4>3.0.co;2-j.
7
Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.186例局部晚期肢体软组织肉瘤患者采用肿瘤坏死因子与美法仑进行隔离肢体灌注以挽救肢体。欧洲多中心累积经验。
Ann Surg. 1996 Dec;224(6):756-64; discussion 764-5. doi: 10.1097/00000658-199612000-00011.
8
Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.在采用化疗药物进行的肢体隔离灌注治疗失败后,对肢体黑色素瘤患者进行肿瘤坏死因子和马法兰的肢体隔离再灌注治疗。
Cancer. 1997 Dec 1;80(11):2084-90. doi: 10.1002/(sici)1097-0142(19971201)80:11<2084::aid-cncr7>3.0.co;2-x.
9
Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.在使用肿瘤坏死因子-α和美法仑进行热灌注隔离肢体治疗期间,用放射性碘-131标记的人血清白蛋白进行持续渗漏监测的价值。
Ann Surg Oncol. 2002 May;9(4):355-63. doi: 10.1007/BF02573870.
10
Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.美法仑与肿瘤坏死因子-α 进行离体肢体灌注后的局部毒性与单独使用美法仑后的毒性比较。
Eur J Surg Oncol. 2001 Jun;27(4):390-5. doi: 10.1053/ejso.2001.1124.

引用本文的文献

1
Anaesthesia for isolated limb perfusion.肢体隔离灌注麻醉
BJA Educ. 2025 Apr;25(4):155-162. doi: 10.1016/j.bjae.2024.12.002. Epub 2025 Feb 6.
2
Engineering a versatile and retrievable cell macroencapsulation device for the delivery of therapeutic proteins.设计一种用于递送治疗性蛋白质的多功能且可回收的细胞宏观封装装置。
iScience. 2023 Jul 13;26(8):107372. doi: 10.1016/j.isci.2023.107372. eCollection 2023 Aug 18.
3
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
间皮素靶向嵌合抗原受体T细胞疗法的局部递送可产生强大且持久的CD4依赖性肿瘤免疫。
Sci Transl Med. 2014 Nov 5;6(261):261ra151. doi: 10.1126/scitranslmed.3010162.
4
Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.TNFerade 生物制剂联合氟尿嘧啶和放疗治疗局部晚期胰腺癌的随机 III 期多中心研究:最终结果。
J Clin Oncol. 2013 Mar 1;31(7):886-94. doi: 10.1200/JCO.2012.44.7516. Epub 2013 Jan 22.
5
Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters.分析采用现代治疗参数行孤立肢体灌注治疗转移性黑色素瘤患者的预后影响因素。
J Clin Oncol. 2010 Jan 1;28(1):114-8. doi: 10.1200/JCO.2009.23.7511. Epub 2009 Nov 9.
6
Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins.接受重组白细胞介素-21治疗的晚期癌症患者的免疫激活:血清蛋白的多分析物谱分析
Cancer Immunol Immunother. 2009 Jun;58(6):843-54. doi: 10.1007/s00262-008-0600-8. Epub 2008 Oct 17.
7
One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases.对患有多处皮肤转移的黑色素瘤患者进行了100次连续的肿瘤坏死因子-α和美法仑隔离肢体灌注。
Ann Surg. 2004 Dec;240(6):939-47; discussion 947-8. doi: 10.1097/01.sla.0000146147.89667.ed.
8
Management of in-transit melanoma of the extremity with isolated limb perfusion.
Curr Treat Options Oncol. 2004 Jun;5(3):173-84. doi: 10.1007/s11864-004-0009-3.
9
Transcriptional control of viral gene therapy by cisplatin.顺铂对病毒基因治疗的转录控制。
J Clin Invest. 2002 Aug;110(3):403-10. doi: 10.1172/JCI15548.
10
Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.186例局部晚期肢体软组织肉瘤患者采用肿瘤坏死因子与美法仑进行隔离肢体灌注以挽救肢体。欧洲多中心累积经验。
Ann Surg. 1996 Dec;224(6):756-64; discussion 764-5. doi: 10.1097/00000658-199612000-00011.